Acute pulmonary exacerbation and lung function decline in patients with cystic fibrosis: High-mobility group box 1 (HMGB1) between inflammation and infection

Clinical Microbiology and Infection

Volumn 21, Issue 4, 2015, Pages 368.e1-368.e9

  Chirico, V ^a   Lacquaniti, A ^a   Leonardi, S ^b   Grasso, L ^a   Rotolo, N ^b   Romano, C ^a   Di Dio, G ^b   Lionetti, E ^b   David, A ^a   Arrigo, T ^a   Salpietro, C ^a   La Rosa, M ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Acute pulmonary exacerbation; Cystic fibrosis; HMGB1; Lung function decline; Pulmonary Pseudomonas infection

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; HMGB1 PROTEIN, HUMAN;

ACUTE PULMONARY EXACERBATION; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DETERIORATION; DISEASE COURSE; DISEASE EXACERBATION; EVOLUTION; FEMALE; FOLLOW UP; HUMAN; INFECTION; INFLAMMATION; LUNG FIBROSIS; LUNG FUNCTION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SPUTUM LEVEL; ADOLESCENT; BLOOD; BRONCHOPNEUMONIA; CHEMISTRY; CHILD; COMPLICATION; LUNG FUNCTION TEST; PATHOLOGY; PRESCHOOL CHILD; PROSPECTIVE STUDY; SERUM; SPUTUM; YOUNG ADULT;

PSEUDOMONAS;

ADOLESCENT; ADULT; BRONCHOPNEUMONIA; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; HMGB1 PROTEIN; HUMANS; INFLAMMATION; MALE; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS; SERUM; SPUTUM; YOUNG ADULT;

EID: 84928559004     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2014.11.004     Document Type: Article

References (28)

1. Yankaskas J.R., Marshall B.C., Sufian B., Simon R.H., Rodman D. Cystic fibrosis adult care: consensus conference report. Chest 2004, 125(Suppl.1):1S-39S.
2. Rivas Caldas R., Boisramé S. Upper aero-digestive contamination by Pseudomonas aeruginosa and implications in Cystic Fibrosis. JCyst Fibros 2014 Jun 2, pii: S1569-1993(14)00095-2. [Epub ahead of print]. 10.1016/j.jcf.2014.04.008.
3. Daines C., VanDeVanter D., Khan U., Emerson J., Heltshe S., McNamara S., et al. Serology as a diagnostic tool for predicting initial Pseudomonas aeruginosa acquisition in children with cystic fibrosis. JCyst Fibros 2014, 13:542-549.
4. Sanders D.B. Phenotypes that matter: Pseudomonas aeruginosa and progression of cystic fibrosis lung disease. Am J Respir Crit Care Med 2014, 190:245-246.
5. Elizur A., Cannon C.L., Ferkol T.W. Airway inflammation in cystic fibrosis. Chest 2008, 133:489-495.
6. Volpi S., Marostica A., D'Orazio C., Amenta G., Pintani E., Baroukh A. Is lung function worsening during adolescence in cystic fibrosis? A retrospective study. Eur Respir J 2012, 40:P3370.
7. Mayer-Hamblett N., Aitken M.L., Accurso F.J., Kronmal R.A., Konstan M.W., Burns J.L., et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med 2007, 175:822-828.
8. Neri G., Lacquaniti A., Rizzo G., Donato N., Latino M., Buemi M. Real-time monitoring of breath ammonia during haemodialysis: use of ion mobility spectrometry (IMS) and cavity ring-down spectroscopy (CRDS) techniques. Nephrol Dial Transplant 2012, 27:2945-2952.
9. Monge M.E., Pérez J.J., Dwivedi P., Zhou M., McCarty N.A., Stecenko A.A., et al. Ion mobility and liquid chromatography/mass spectrometry strategies for exhaled breath condensate glucose quantitation in cystic fibrosis studies. Rapid Commun Mass Spectrom 2013, 27:2263-2271.
10. Sloane A.J., Lindner R.A., Prasad S.S., Sebastian L.T., Pedersen S.K., Robinson M., et al. Proteomic analysis of sputum from adults and children with cystic fibrosis and from control subjects. Am J Respir Crit Care Med 2005, 172:1416-1426.
11. Arrigo T., Chirico V., Salpietro V., Munafò C., Ferraù V., Gitto E., et al. High-mobility group protein B1: a new biomarker of metabolic syndrome in obese children. Eur J Endocrinol 2013, 168:631-638.
12. Salpietro C., Cuppari C., Grasso L., Tosca M.A., Miraglia Del Giudice M., La Rosa M., et al. Nasal high-mobility group box-1 protein in children with allergic rhinitis. Int Arch Allergy Immunol 2013, 161:116-121.
13. Chirico V., Lacquaniti A., Salpietro V., Munafò C., Calabrò M.P., Buemi M., et al. High-mobility group box 1 (HMGB1) in childhood: from bench to bedside. Eur J Pediatr 2014, 173:1123-1136.
14. Rowe S.M., Jackson P.L., Liu G., Hardison M., Livraghi A., Solomon G.M., et al. Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med 2008, 178:822-831.
15. Sagel S.D., Wagner B.D., Anthony M.M., Emmett P., Zemanick E.T. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Am J Respir Crit Care Med 2012, 186:857-865.
16. Liou T.G., Adler F.R., Keogh R.H., Li Y., Jensen J.L., Walsh W., et al. Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis. PLoS One 2012, 7:e42748.
17. Rosenstein B.J., Cutting G.R. The diagnosis of cystic fibrosis: a consensus statement. Cystic fibrosis foundation consensus panel. JPediatr 1998, 132:589-595.
18. Wang X., Dockery D.W., Wypij D., Fay M.E., Ferris B.G. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993, 15:75-88.
19. Baker R.D. Assessing exocrine pancreatic function: when the best test is not possible. JPediatr Gastroenterol Nutr 2013, 56:116-117.
20. Sagel S.D., Kapsner R., Osberg I., Sontag M.K., Accurso F.J. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med 2001, 164:1425-1431.
21. Burns J.L., Emerson J., Stapp J.R., Yim D.L., Krzewinski J., Louden L., et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998, 27:158-163.
22. Fuchs H.J., Borowitz D.S., Christiansen D.H., Morris E.M., Nash M.L., Ramsey B.W., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The pulmozyme study group. NEngl J Med 1994, 331:637-642.
23. Liu G., Wang J., Park Y.J., Tsuruta Y., Lorne E.F., Zhao X., et al. High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine. JImmunol 2008, 181:4240-4246.
24. Gaggar A., Rowe S.M., Hardison M., Blalock J.E. Proline-glycine-proline (PGP) and high mobility group box protein-1 (HMGB1): potential mediators of cystic fibrosis airway inflammation. Open Respir Med J 2010, 4:32-38.
25. Abraham E., Arcaroli J., Carmody A., Wang H., Tracey K.J. Cutting edge: HMG-1 as a mediator of acute lung inflammation. JImmunol 2000, 165:2950-2954.
26. Entezari M., Weiss D.J., Sitapara R., Whittaker L., Wargo M.J., Li J., et al. Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas aeruginosa pneumonia in cystic fibrosis. Mol Med 2012, 18:477-485.
27. Junkins R.D., McCormick C., Lin T.J. The emerging potential of autophagy-based therapies in the treatment of cystic fibrosis lung infections. Autophagy 2014, 10:538-547.
28. Paul K., Rietschel E., Ballmann M., Griese M., Worlitzsch D., Shute J., et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004, 169:719-725.